Korean Medication Algorithm Project for Bipolar Disorder 2022: Comparisons with Other Treatment Guidelines

Area of Science:

• Psychiatry
• Pharmacology
• Clinical Practice Guidelines

Background:

• Bipolar disorder treatment requires updated guidelines.
• Global variations in treatment recommendations exist.
• The Korean Medication Algorithm Project for Bipolar Disorder (KMAP-BP) provides specific recommendations.

Purpose of the Study:

• To compare KMAP-BP 2022 recommendations with other recent global bipolar disorder treatment guidelines.
• To identify similarities and differences in treatment strategies.
• To evaluate the KMAP-BP 2022's alignment with international standards.

Main Methods:

• Review of six recent global bipolar disorder treatment guidelines.
• Comparative analysis of KMAP-BP 2022 with reviewed guidelines.
• Focus on initial treatment, specific phases, and combination therapies.

Main Results:

• No significant differences in initial mania treatment recommendations across guidelines.
• KMAP-BP 2022 uniquely recommends mood stabilizer (MS) + atypical antipsychotic (AAP) combination therapy as a first-line choice for psychotic mania, mixed mania, and psychotic depression.
• Aripiprazole, quetiapine, and olanzapine are consistently recommended first-line AAPs; newer AAPs and lamotrigine are also highlighted.
• Lithium and valproic acid are common MSs across all phases.

Conclusions:

• KMAP-BP 2022 guidelines reflect current research and global trends in bipolar disorder pharmacotherapy.
• The algorithm's distinct emphasis on combination therapy for severe presentations warrants attention.
• KMAP-BP 2022 offers a valuable, updated perspective on bipolar disorder management.